Cardiovascular
Cardiovascular
0
Pipeline Programs↗
28
Active Trials↗
22
Companies Involved↗
Cardiovascular is an early-stage landscape with 0 programs across 22 companies. The most active players are Novartis, Amgen, Bayer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
162
clinical trials
Completed95 · 59%
Unknown status20 · 12%
Recruiting19 · 12%
Terminated11 · 7%
Withdrawn8 · 5%
Not yet recruiting4 · 2%
Other5 · 3%
Clinical Trials
Trial Activity
162 trials
FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort
Recruiting·—·N/A·NCT05916287·3,000 enrolled
Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial
Recruiting·—·Phase 4·NCT05932472·32,706 enrolled
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
Recruiting·—·Phase 4·NCT06650488·300 enrolled
Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS
Recruiting·—·N/A·NCT06889454·120 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)